The results of the study revealed that supplementation with n-3 PUFAs in MS significantly decreased ApoB (0.94 ± 0.36 vs. 1.13 ± 0.35, p = 0.001) and homocysteine (13.78 ± 3.05 vs. 19.3 ± 5.29, p = 0.001) and, concurrently, increased GPX (41.65 ± 8.90 vs. 45.20 ± 8.01, p = 0.001). Here, APOB is linked to myeloid sarcoma.